{"title":"推进对转移性非小细胞肺癌患者的精准靶向治疗。","authors":"Tajuana Bradley, Beth Sandy","doi":"10.6004/jadpro.2024.15.3.7","DOIUrl":null,"url":null,"abstract":"<p><p>At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non-small cell lung cancer.</p>","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 3","pages":"170-176"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406318/pdf/","citationCount":"0","resultStr":"{\"title\":\"Advancing Precision-Targeted Treatment for Patients With Metastatic Non-Small Cell Lung Cancer.\",\"authors\":\"Tajuana Bradley, Beth Sandy\",\"doi\":\"10.6004/jadpro.2024.15.3.7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non-small cell lung cancer.</p>\",\"PeriodicalId\":94110,\"journal\":{\"name\":\"Journal of the advanced practitioner in oncology\",\"volume\":\"15 3\",\"pages\":\"170-176\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406318/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the advanced practitioner in oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.6004/jadpro.2024.15.3.7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the advanced practitioner in oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.6004/jadpro.2024.15.3.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在 JADPRO Live 2023 上，演讲者讨论了生物标记物检测的意义、导致最近获得 FDA 批准的关键临床试验，以及监测和管理转移性非小细胞肺癌患者分子靶向疗法和联合疗法相关不良事件的循证最佳实践。
Advancing Precision-Targeted Treatment for Patients With Metastatic Non-Small Cell Lung Cancer.
At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non-small cell lung cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
